CCRM’s scientific expertise, coupled with our approach to project management, allows us to work collaboratively with both emerging biotech start-ups and academic as they begin to take their products from concept to market. CCRM’s development, scale-up/out and manufacturing capabilities include:
- Good Manufacturing Practices (GMP), induced pluripotent stem cell (iPSC) reprogramming, gene editing and differentiation
- Automated, closed, integrated, process development (PD) and manufacturing for T-cells and natural killer (NK) cells (e.g. CAR-T, CAR-NK)
- Viral vector (lentivirus, adeno-associated virus, other) upstream and downstream process development and optimization for manufacturing
- GMP-compliant manufacturing of master/working cell banks
- Analytical development including high-throughput screening assays, quality control (QC) testing, and ICH stability studies
- Assessment of next-generation bioprocessing hardware and technologies
- Custom and high-throughput media development
- Hematopoietic stem cell isolation and processing
- Cryopreservation strategies
- In-house QC to support product release
- Pre-clinical and clinical regulatory consulting
Find out more about our extensive expertise
Learn more about the other pillars in our approach:
Customer Testimonials
We’ve found an ongoing partner [in CCRM]
– Dr. Ralph Brandenberger, SVP Technical Operations, Nkarta
[The team] really helped us get to where we are today.
– Dr. Lara Ionescu Silverman, PhD, Senior Director, Research and Development, DiscGenics
It almost felt like they [CCRM] were an extension of our team. The culture and adaptive nature, flexibility and communication were excellent.
– Edel O’Toole, Senior Director Project & Vendor Management, Avectas
